MedTrace Logo

A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)

NCT06625840 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-10-03

No results posted yet for this study

Summary

The goal of this study is to learn how safe MK-1167 is in healthy elderly adults and how well people tolerate it.

Conditions

  • Healthy

Interventions

DRUG

MK-1167

Oral Administration

DRUG

Placebo

Oral Administration

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-18
Primary Completion
2024-05-08
Completion
2024-05-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06625840 on ClinicalTrials.gov